Q1 2025

Filed May 5, 2025 · 10-Q · 35 days after period end · 0000950170-25-063518

Q1 2025 · 10-Q

Revenue

$20.04M

— vs Q1 2024

Net Income

-$84.85M

N/M vs Q1 2024

EPS Diluted

-$0.98

N/M vs Q1 2024

Operating Income-$83,757,000N/M

Operating Cash Flow

Same quarter

Metric	Q1 2025	Q1 2024	Q1 2023	Q1 2022
Revenue	$20.04M	$0.00	—	—
Net Income	-$84.85M	-$72.40M	-$41.13M	-$37.17M
EPS Diluted	-$0.98	-$0.85	-$0.59	-$0.63

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Syndax Pharmaceuticals Inc · CIK 1395937 · Engraved from SEC EDGAR